Equity
Common Stock
Vertex Pharmaceuticals Common Stock decreased by 99.5% to $2.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 3.8%, from $2.60M to $2.50M. Over 5 years (FY 2020 to FY 2025), Common Stock shows relatively stable performance with a -0.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
Changes are typically driven by share issuances or buybacks, reflecting capital allocation decisions.
Detailed definition
This represents the par value of the common shares issued by the company. It is a component of shareholders' equity and...
Peer comparison
A standard equity line item found on the balance sheets of all publicly traded companies.
Metric ID:
common_stockHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $500.00M | $500.00M | $2.50M | $500.00M | $500.00M | $500.00M | $2.60M | $500.00M | $500.00M | $500.00M | $2.60M | $500.00M | $500.00M | $500.00M | $2.60M | $500.00M | $500.00M | $500.00M | $2.50M |
| QoQ Change | — | +0.0% | -99.5% | >999% | +0.0% | +0.0% | -99.5% | >999% | +0.0% | +0.0% | -99.5% | >999% | +0.0% | +0.0% | -99.5% | >999% | +0.0% | +0.0% | -99.5% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +4.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -3.8% |
Range$2.50M – $500.00M
CAGR-69.2%
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Common Stock at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's common stock?
- Vertex Pharmaceuticals (VRTX) reported common stock of $2.50M in Q4 2025.
- How has Vertex Pharmaceuticals's common stock changed year-over-year?
- Vertex Pharmaceuticals's common stock decreased by 3.8% year-over-year, from $2.60M to $2.50M.
- What is the long-term trend for Vertex Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's common stock has grown at a -0.8% compound annual growth rate (CAGR), from $2.60M to $2.50M.
- What does common stock mean?
- The accounting value of the company's issued common shares.